Fabino Enterprises Limited (FABINO) Fair Value & Analysis
Healthcare · IN · Market cap ₹42.7M
Fair value as of: Jul 5, 2026
From 6 valuation models · updated today
Price vs Fair Value (12 months)
12‑month range ₹13.10 – ₹28.10 · fair‑value band ₹0.7780 – ₹7.10 · the ₹20.31 price screens above the ₹3.89 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Fabino Enterprises Limited (FABINO) currently trades at ₹20.31, while our model-based Fair Value estimate is ₹3.89 — implying the stock looks roughly 80.8% overvalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Fabino Enterprises Limited generated revenue of ₹208M at a net margin of -2.7%. Revenue grew 2.9% year over year. It earns a return on equity of -14.2%. Net debt stands at ₹14.3M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹0.7780 (bear case) to ₹7.10 (bull case); at ₹20.31, the current price sits above that range. The share trades about 28% below its 52-week high and 55% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside — at -81%, FABINO screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Fabino Enterprises Limited, a pharmaceutical company, develops, manufactures, markets, trades in, and packages pharmaceutical and other wellness focused consumer products in India. The company offers allopathic, Covid-19, herbal, veterinary, and multi vitamin products, as well as food and wellness products under the Fabino and Keepshine brand names. It also exports wellness and FMCG products, such as coffee, malt powder, protein powder, hair shampoo, etc. The company markets its products through its own distribution network and sales force. The company was formerly known as Fabino Life Sciences Limited and changed its name to Fabino Enterprises Limited in June 2024. Fabino Enterprises Limited was incorporated in 2011 and is based in Sonipat, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Fabino Enterprises Limited reported revenue of ₹208M in FY2026 versus ₹42.0M in FY2022, a compound +49.2%/yr. Reported net income was −₹5.6M in FY2026.
Is FABINO fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹991.46 | -47% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fabino Enterprises Limited (FABINO) undervalued?
What is the fair value of FABINO?
What is the quality score of FABINO?
What is the revenue of Fabino Enterprises Limited (FABINO)?
What is the net profit margin of FABINO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.